Because VMAT2 inhibitors are not yet approved for the treatment of tics associated with TS, these drugs are not frequently prescribed globally for this indication, although we have had a long-term experience with these dopamine depleters at Baylor College of Medicine [19, 21]. The gene discussed is SLC18A2; the disease is Timothy syndrome.